BRPI0412607A - método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes - Google Patents

método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes

Info

Publication number
BRPI0412607A
BRPI0412607A BRPI0412607-6A BRPI0412607A BRPI0412607A BR PI0412607 A BRPI0412607 A BR PI0412607A BR PI0412607 A BRPI0412607 A BR PI0412607A BR PI0412607 A BRPI0412607 A BR PI0412607A
Authority
BR
Brazil
Prior art keywords
protein variant
efficacy
enhancing
biological reaction
modifying proteins
Prior art date
Application number
BRPI0412607-6A
Other languages
English (en)
Inventor
Yong-Hoon Chung
Hak-Sup Lee
Ki-Wan Yi
Youn-Hwa Heo
Jae-Youn Kim
Original Assignee
Medexgen Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medexgen Co Ltd filed Critical Medexgen Co Ltd
Publication of BRPI0412607A publication Critical patent/BRPI0412607A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

MéTODO PARA APRIMORAR A EFICáCIA DE PROTEINAS MODIFICANTES DE REAçãO BIOLóGICA E MUTEìNAS RESULTANTES A presente patente de invenção descreve uma variante de proteína que substitui resíduo de fenilalanina por valina em um meio de ligação possuindo função modificadora de reação biológica pela ligação a um receptor, agente de ligação ou substrato. Também, a presente invenção descreve um DNA que codifica uma variante de protéina, um vetor de expressão recombinante no qual o DNA é operacionalmente ligado, uma célula hospedeira transformada ou transfectada com o vetor de expressão recombinante, e um método para o preparo da variante de proteína compreendendo o cultivo da célula hospedeira e o isoladamente da variante de protéina da cultura resultante. Ademais, a presente invenção descreve uma composição farmacêuticamente possuindo a variante de protéina e uma enzima farmacologicamente aceitável.
BRPI0412607-6A 2003-07-26 2004-05-27 método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes BRPI0412607A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030051846A KR100632985B1 (ko) 2003-07-26 2003-07-26 생리활성 조절 단백질의 효능 향상 방법 및 그 예시변이체들
PCT/KR2004/001246 WO2005010043A1 (en) 2003-07-26 2004-05-27 A method of improving efficacy of biological response-modifying proteins and the exemplary muteins

Publications (1)

Publication Number Publication Date
BRPI0412607A true BRPI0412607A (pt) 2007-07-03

Family

ID=36284112

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412607-6A BRPI0412607A (pt) 2003-07-26 2004-05-27 método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes

Country Status (14)

Country Link
US (3) US7569361B2 (pt)
EP (1) EP1668030B1 (pt)
JP (1) JP4747238B2 (pt)
KR (1) KR100632985B1 (pt)
CN (2) CN102286090A (pt)
AT (1) ATE500266T1 (pt)
AU (1) AU2004259314B2 (pt)
BR (1) BRPI0412607A (pt)
CA (1) CA2528458A1 (pt)
DE (1) DE602004031642D1 (pt)
ES (1) ES2362453T3 (pt)
RU (1) RU2432360C2 (pt)
WO (1) WO2005010043A1 (pt)
ZA (1) ZA200600502B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1539960B1 (en) * 2002-09-09 2010-04-28 Hanall Pharmaceutical Co., Ltd. Protease-resistant modified interferon alpha polypeptides
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
CA2607806A1 (en) * 2005-05-04 2006-11-16 Nautilus Biotech, S.A. Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
KR101510743B1 (ko) 2013-07-23 2015-04-10 (주)케어젠 파골 세포 분화 억제용 펩타이드 및 이의 용도
US10052343B1 (en) * 2017-02-03 2018-08-21 Gene Signal International Sa Sterile formulation comprising a stable phosphorothioate oligonucleotide
EP3596108A4 (en) 2017-03-15 2020-12-23 Pandion Operations, Inc. TARGETED IMMUNOTOLERANCE
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
US10676516B2 (en) 2017-05-24 2020-06-09 Pandion Therapeutics, Inc. Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
KR20240046306A (ko) 2020-01-14 2024-04-08 신테카인, 인크. 편향된 il2 뮤테인 방법 및 조성물
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
WO2024099445A1 (zh) * 2022-11-10 2024-05-16 康立泰生物医药(青岛)有限公司 聚乙二醇定点修饰异源聚体蛋白或多肽及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3923963A1 (de) * 1989-07-20 1991-01-31 Behringwerke Ag Muteine des menschlichen erythropoetins, ihre herstellung und ihre verwendung
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
AU3538799A (en) * 1998-04-30 1999-11-23 Kirin Brewery Company, Limited Human thrombopoietin mutants
WO2003104263A2 (en) * 2002-05-01 2003-12-18 Genencor International, Inc. Cytokines and cytokine receptors with reduced immunogenicity

Also Published As

Publication number Publication date
US20060008872A1 (en) 2006-01-12
RU2006102846A (ru) 2007-09-10
KR20050013024A (ko) 2005-02-02
CN101384620A (zh) 2009-03-11
EP1668030B1 (en) 2011-03-02
RU2432360C2 (ru) 2011-10-27
EP1668030A4 (en) 2006-06-14
JP4747238B2 (ja) 2011-08-17
CN101384620B (zh) 2011-08-17
EP1668030A1 (en) 2006-06-14
WO2005010043A1 (en) 2005-02-03
ATE500266T1 (de) 2011-03-15
JP2007524403A (ja) 2007-08-30
US20130089513A1 (en) 2013-04-11
ZA200600502B (en) 2007-02-28
US20100041586A1 (en) 2010-02-18
DE602004031642D1 (de) 2011-04-14
US7569361B2 (en) 2009-08-04
AU2004259314B2 (en) 2006-12-07
CA2528458A1 (en) 2005-02-03
KR100632985B1 (ko) 2006-10-11
ES2362453T3 (es) 2011-07-05
AU2004259314A1 (en) 2005-02-03
CN102286090A (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
BRPI0412607A (pt) método para aprimorar a eficácia de proteìnas modificantes de reação biológica e muteìnas resultantes
Banerjee et al. Kinetics of colchicine binding to purified beta-tubulin isotypes from bovine brain.
MX348154B (es) Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
MXPA05014215A (es) Mapeo de genoma de elementos funcionales de adn y proteinas celulares.
WO2006014349A3 (en) Method of producing fully carbamylated erythropoietin
EA021222B8 (ru) Биологически активные белки, имеющие повышенную стабильность in vivo и/или in vitro
EP2540309A3 (en) Tissue protective peptides and uses thereof
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
NO20064134L (no) Modifiserte bouganinproteiner, cytotoksiner og fremgangsmater og anvendelser derav
WO2006116181A3 (en) Regulatory t cell mediator proteins and uses thereof
WO2003020932A1 (fr) Nouvelles proteines de secretion et adn associe
DE69808743T2 (de) Netrinrezeptoren
WO2006028561A3 (en) Novel purified fabi polypeptides from fransicella tularensis
WO2007013358A3 (en) Vivit polypeptides, therapeutic agent comprising the same, and method of screening for anti-cancer agent
BRPI0409554A (pt) peptacorpo de fusão isolado e recombinante, seqüência de dna, vetor, célula hospedeira, composição farmacêutica e seu uso, kits, método para a produção do peptacorpo de fusão e seqüência de intensificador
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
Chingle et al. Azopeptides: Synthesis and pericyclic chemistry
Antonyan et al. Proline-rich cytokine from neurosecretory granules: A new natural substrate for dipeptidyl peptidase IV
JP2007529475A (ja) 等比体積の形態変換
WO2005097830A3 (en) Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds
WO2003082897A3 (en) Synthetic active peptide fragments
EP1578953A4 (en) METHOD FOR DETERMINING THE PRIMARY STRUCTURE OF THE BOTENNA RNA CODING FOR THE RECOMBINANT HUMAN ENDOOLIGOPEPTIDASE A (HEOPA) ¬AF217798 |
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
DE60032161D1 (de) P-glycoproteine und ihre verwendungen
IL151211A0 (en) Compositions useful for regulating parkin gene activity

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE.

B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: NAO CONHECIDA A PETICAO 20110023284 DE 11/03/2011 COM BASE NO DISPOSTO NO ART 219, INCISO "I" DA LPI E NOS ARTIGOS 10 AO 14 DA RESOLUCAO INPI/DIRPA NO 124/2006 EM VIRTUDE DE TER SIDO APRESENTADA APOS O PRAZO LEGAL DE 03 (TRES) MESES, TENDO COMO INICIO PARA A CONTAGEM DO PRAZO O DESPACHO 8.6 PUBLICADO NA RPI 2082 DE 30/11/2010.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2082 DE 30/11/2010 E CONSIDERANDO A MANIFESTACAO INTEMPESTIVA REFERENTE A PUBLICACAO SUPRA, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE.